The present analysis from an all-comers clinical registry demonstrates that during the last 14 years STEMI-patients with advanced CKD, which constituted 11% of the total cohort, were more likely to be treated with emergency PCI and are in their majority now treated with DES and the more potent P2Y12-inhibitors ticagrelor and prasugrel. Here, P2RY12 is linked to chronic kidney disease.